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Abstract
Objective To summarise the effect of primary
prevention with lipid lowering drugs on coronary
heart disease events, coronary heart disease mortality,
and all cause mortality.
Design Meta-analysis.
Identification Systematic search of the Medline
database from January 1994 to June 1999 for English
language studies examining drug treatment for lipid
disorders (use of the MeSH terms “hyperlipidemia”
and “anticholesteremic agents,” keyword searches for
individual drug names, and a search strategy for
identifying randomised trials to capture relevant
articles); identification of older studies through
systematic reviews and hand search of bibliographies.
Inclusion criteria All randomised trials of at least one
year’s duration that examined drug treatment for
patients with no known coronary heart disease,
cerebrovascular disease, or peripheral vascular disease
and that measured clinical end points, including all
cause mortality, coronary heart disease mortality, and
non-fatal myocardial infarctions.
Data extraction Review of the articles and extracted
relevant data by two authors separately, with
disagreements resolved by consensus.
Results Four studies met eligibility criteria. Drug
treatment reduced the odds of a coronary heart
disease event by 30% (summary odds ratio 0.70, 95%
confidence interval 0.62 to 0.79) but not the odds of
all cause mortality (0.94, 0.81 to 1.09). When statin
drugs were considered alone, no substantial
differences in results were found.
Conclusions Treatment with lipid lowering drugs
lasting five to seven years reduces coronary heart
disease events but not all cause mortality in people
with no known cardiovascular disease.
Introduction
The effectiveness of drug treatment for lipid disorders
in patients with no history of coronary heart disease
has been controversial.1–3 Although the effectiveness of
lipid lowering agents for secondary prevention in
people with lipid disorders is strongly supported,
primary prevention trials and systematic reviews have
reached mixed conclusions about the effect of lipid
lowering on mortality from coronary heart disease and
on all cause mortality. Earlier reviews cautioned against
drug treatment in patients with low to moderate risk of
death from coronary heart disease because of possible
increases in all cause mortality with treatment.4 A more
recent review of lipid lowering treatment with
hydroxymethyl glutaryl coenzyme A reductase inhibi-
tors (statins) found that coronary heart disease events
and all cause mortality were decreased in primary pre-
vention populations.5 Reviews, however, have not
included data from the large air force/Texas coronary
prevention study (AFCAPS/TexCAPS), which exam-
ined the effect of drug treatment in men and women
with poor ratios of total cholesterol concentration to
high density lipoprotein cholesterol concentration and
a modest risk (0.5-1% a year) of coronary heart disease
events.6
We performed an updated systematic review and
quantitative meta-analysis of primary prevention trials
to estimate the effect of lipid lowering drugs on the
incidence of coronary heart disease events (defined as
non-fatal myocardial infarction and deaths from
coronary heart disease), on coronary heart disease
mortality, and on all cause mortality.
Methods
We searched the Medline database for articles
published from January 1994 to June 1999, using the
MeSH subject headings “hyperlipidemia” and “anti-
cholesteremic agents,” MeSH terms or keywords for
individual drug names, and a combination of subject
headings and key words designed to identify
randomised trials. We also searched the clinical trials
registry of the Cochrane Library (Oxford, UK: Update
Software, 1999) to identify studies that were not
included in Medline. We used the bibliographies of sys-
tematic reviews and clinical practice guidelines to iden-
tify older trials not found through our main search
strategy.
Two authors (MP and CP) separately reviewed the
abstracts produced by the literature search to identify
studies that were randomised trials which lasted at least
one year and which measured clinical end points,
including coronary heart disease events, coronary
heart disease mortality, and all cause mortality. We
excluded non-randomised studies, trials lasting less
than one year, and trials examining only the change in
serum cholesterol concentrations or angiographic out-
comes. We also excluded studies published in
languages other than English, studies published in
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abstract form only, and studies of secondary preven-
tion that enrolled primarily patients with known
coronary heart disease, cerebrovascular disease, or
peripheral vascular disease. Studies that included a
mixture of primary and secondary prevention patients
were excluded if the results could not be distinguished
for each group. If the information in the abstract was
insufficient to determine eligibility for this review or if
the reviewers disagreed about eligibility, we carried the
article forward to the next stage.
We then reviewed the full articles for eligibility. For
articles meeting inclusion criteria, we extracted the rel-
evant data and entered them into evidence tables.
Meta-analysis was performed with the Peto method for
fixed effects models and then the DerSimonian and
Laird method for random effects models. Graphs of
the outcomes for included trials were examined
visually and by using the ÷2 test to identify
heterogeneity in the outcome variables across different
studies. Because the results of our meta-analysis did
not differ according to whether the fixed or random
effects model was used, we present only the fixed effects
results here. The results are displayed as summary
odds ratios and 95% confidence intervals for the effect
of drug treatment on total coronary heart disease
events, coronary heart disease mortality alone, and all
cause mortality.
We performed a sensitivity analysis on the effect of
including or excluding certain trials by repeating the
meta-analysis after adding four trials that were difficult
to categorise as primary prevention or mixed primary
and secondary prevention. These four studies included
three in which the eligibility of participants and the
primary outcome measures were based on the degree
of atherosclerosis in the femoral or carotid arteries that
had been determined with ultrasonography7-9 and one
that used clofibrate,10 a drug that is not currently used
for lipid lowering in the United States.
Finally, because a previous meta-analysis had
examined the effect of statins alone,5 we also analysed
the three trials that used statins and compared the
result of this analysis with our overall result.
Results
Literature search
Our searches identified 516 articles, of which 448 were
rejected after the abstract was reviewed. The remaining
68 articles included 34 that were rejected because they
involved secondary prevention populations; 10 that
were rejected because they had mixed primary and
secondary prevention groups,11-15 were not ran-
domised,16 or did not measure relevant end points17-20;
16 articles with supplemental information only; 4 arti-
cles that met all inclusion criteria; and 4 studies that
were considered to be “possibly suitable for
inclusion.’’7-10
Trial characteristics
The four eligible studies were the Lipid Research
Clinic primary prevention trial, the Helsinki heart
study, the west of Scotland coronary prevention study,
and the air force/Texas coronary prevention study.6 21-23
The table shows the basic study characteristics.
Main results
Figure 1 shows the effect of treatment with lipid lower-
ing drugs on coronary heart disease events, coronary
Study characteristics
LRC HHS WOSCOPS AFCAPS/TexCAPS




Pravastatin (40 mg four
times daily)
Lovastatin (20-40 mg four times
daily)
Study duration (years) 7 5 5 5
No of subjects (intervention/control) 1906/1900 2051/2030 3302/3293 3304/3301
Mean age (years) 48 47 55 58
% of male subjects 100 100 100 85
Mean initial total cholesterol (mmol/l) 7.5 7.4 7.0 5.7
Mean reduction in total cholesterol (%) 8.5† 10‡ 20‡ 18§
LRC=Lipid Research Clinic primary prevention trial; HHS=Helsinki heart study; WOSCOPS=west of Scotland coronary prevention study; AFCAPS/TexCAPS=air
force/Texas coronary prevention study.












































0.81 (0.65 to 1.01)
0.65 (0.46 to 0.92)
0.68 (0.56 to 0.83)
0.58 (0.41 to 0.80)
0.70 (0.62 to 0.79)


























0.78 (0.48 to 1.27)
0.73 (0.36 to 1.45)
0.68 (0.47 to 0.98)
0.68 (0.37 to 1.26)
0.71 (0.56 to 0.91)































0.95 (0.68 to 1.34)
1.06 (0.69 to 1.62)
0.78 (0.60 to 1.01)
1.05 (0.83 to 1.32)
0.94 (0.81 to 1.09)
Fig 1 Effect of lipid lowering drugs (compared with placebo) on odds of coronary heart
disease events, coronary heart disease mortality, and all cause mortality (fixed effects model).
LRC=Lipid Research Clinic primary prevention trial; HHS=Helsinki heart study;
WOSCOPS=west of Scotland coronary prevention study; AFCAPS/TexCAPS=air force/Texas
coronary prevention study
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heart disease mortality, and all cause mortality.
Treatment reduced the relative risk of coronary heart
disease events by 30% compared with placebo
(summary odds ratio 0.70, 95% confidence interval
0.62 to 0.79). The relative risk of coronary heart disease
mortality was reduced by 29% (0.71, 0.56 to 0.91).
There was either a small or no effect on all cause mor-
tality (0.94, 0.81 to 1.09). In each of these analyses, the
results of ÷2 tests for heterogeneity were not significant
(P > 0.10).
Sensitivity analysis
As figure 2 shows, the inclusion of the four studies that
were considered possibly suitable for inclusion had
little effect on the estimate of the reduction in coronary
heart disease events (0.72, 0.65 to 0.80). The effect on
coronary heart disease mortality was slightly attenu-
ated for the six studies reporting this outcome (0.76,
0.61 to 0.94), and the effect on all cause mortality
remained non-significant (1.02, 0.89 to 1.15). The ÷2
test for heterogeneity was significant only for the
outcome of all cause mortality, as two trials—the
asymptomatic carotid artery progression study and the
clofibrate cooperative study—had substantially differ-
ent point estimates of effect size.
Figure 3 shows the results of the meta-analysis lim-
ited to the three trials using statins (two from the main
analysis and one of the studies considered to be possi-
bly suitable for inclusion). The summary effect on the
incidence of coronary heart disease events was slightly
greater than for the main analysis (0.65, 0.55 to 0.77),
as was the effect on deaths from coronary heart disease
(0.65, 0.48 to 0.89). The effect on all cause mortality
remained non-significant (0.89, 0.75 to 1.06). Results of
tests for heterogeneity were non-significant for total
coronary heart disease events and coronary heart dis-
ease mortality but were significant (P = 0.04) for all
cause mortality, mainly because of the extreme value
for the asymptomatic carotid artery progression study.
Discussion
Our meta-analysis of primary prevention trials shows
that lipid lowering drugs reduce the relative odds of
coronary heart disease events and coronary heart dis-
ease mortality by about 30% but that their effect on all
cause mortality over five years is small and not signifi-
cant. Limiting the analysis to trials that used statin
drugs suggests a slightly stronger effect on all
outcomes compared with analyses that used all trials,
but it does not show a significant reduction in all cause
mortality.
Our meta-analysis reaches a different conclusion
from that of Hebert et al, who found that statin drugs
reduced all cause mortality (0.74, 0.58 to 0.95).5 Unlike
Hebert et al, we included the results of the large air
force/Texas trial (which had not been published in
1997)6 and did not include the Kuopio atherosclerosis
prevention study, a trial that included some subjects
(10%) with histories of myocardial infarctions.24
The failure of drug treatment to reduce all cause
mortality in primary prevention is most likely due to
the generally low risk of mortality in the patient popu-
lations that were studied rather than some adverse
effect of lipid lowering drugs or of lowering cholesterol
concentrations. Treatment targeted specifically at
primary prevention patients with higher levels of risk
of coronary heart disease events might reduce all cause
mortality. The trial with the participants at highest risk
(west of Scotland coronary prevention study), for
example, found a 22% reduction in the relative risk of
all cause mortality, which was of borderline significance
at five years (P = 0.051).23 Lower risk populations might
also achieve significant reductions in all cause
mortality if they were treated for longer than those
tested in the trials. We have insufficient data, however,
on patients with low levels of risk, such as those
enrolled in the air force/Texas trial, to estimate
precisely the true effect on all cause mortality.
Because the absolute risk of all cause mortality in
primary prevention patients is relatively low (the risk
among control subjects in these trials was only 2-4%
over five years), the absolute benefit in lives saved will
also be low initially. If the true relative risk reduction
for all cause mortality were 10%, the number needed to
treat for five years to prevent one death would be 250
to 500. If it were 20%, it would be 125 to 250. Prevent-
ing non-fatal events may also improve all cause
mortality over a longer span than the five to seven
years observed in these trials, but data about the mag-
nitude of that effect are not currently available.
Study



























































0.79 (0.64 to 0.97)
0.81 (0.65 to 1.01)
0.65 (0.46 to 0.92)
0.55 (0.18 to 1.66)
0.68 (0.56 to 0.83)
1.53 (0.25 to 9.29)
0.33 (0.03 to 3.27)
0.58 (0.41 to 0.80)
0.72 (0.65 to 0.80)




































1.05 (0.66 to 1.68)
0.78 (0.48 to 1.27)
0.73 (0.36 to 1.45)
0.11 (0.01 to 2.06)
0.68 (0.47 to 0.98)
0.68 (0.37 to 1.26)
0.76 (0.61 to 0.94)









































1.44 (1.09 to 1.90)
0.95 (0.68 to 1.34)
1.06 (0.69 to 1.62)
0.12 (0.02 to 0.99)
0.78 (0.60 to 1.01)
1.05 (0.83 to 1.32)
1.02 (0.89 to 1.15)
Fig 2 Analysis as in figure 1 but with inclusion of four studies considered to be “possibly
suitable for inclusion.” ACAPS=asymptomatic carotid artery progression study; Clofibrate
Co-op=clofibrate cooperative study; CAIUS=carotid atherosclerosis Italian ultrasound study;
SENDCAP=St Mary’s, Ealing, Northwick Park diabetes cardiovascular disease prevention study
(for full names of other studies see figure 1)
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The decision about whether to use lipid lowering
drugs for patients with no history of coronary heart
disease is difficult and requires consideration of
outcomes other than all cause mortality. The results of
our meta-analysis suggest that treatment will reduce
the relative risk of coronary heart disease events and
coronary heart disease mortality by about 30%,
independent of absolute risk. The absolute risk reduc-
tion from treatment, therefore, is proportional to the
underlying risk in the person or populations being
considered for treatment. The risk of coronary heart
disease events and mortality, and hence the absolute
risk reduction and number needed to treat, varies con-
siderably in patients with no history of coronary heart
disease and different combinations of coronary heart
disease risk factors. Risk assessment tools can be used
to determine the risk of individual patients and help
providers and patients to decide about treatment.25 26
Generalising these results to other populations—
such as people of non-European descent, women, and
elderly people—is challenging because the included
studies enrolled primarily middle aged men of
European descent. The effect of treatment for women,
elderly people, and men of non-European descent has
not been directly studied, although there is little reason
to believe that the effect would differ for non-
Europeans or elderly people with similar baseline risks
of coronary heart disease and similar lipid abnormali-
ties. Also, the concomitant use of other drugs—such as
chemoprophylaxis with aspirin or treatment with â
blockers, which were not widely prescribed in these
trials—may lower the absolute risk (and thus the poten-
tial absolute risk reductions) for large numbers of
patients at moderate risk of coronary heart disease.
Future research should examine whether the
effects of lipid lowering treatment are similar for
women and for people of non-European origin,
groups that were not well represented in the trials
included here. The effect of longer treatment (5-10
years) should also be examined to determine if it pro-
duces greater reductions in coronary heart disease
events and possibly all cause mortality.
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